Literature DB >> 11530334

Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs).

M B Sporn1, N Suh, D J Mangelsdorf.   

Abstract

Peroxisome proliferator-activated receptor gamma (PPARgamma), a nuclear receptor and transcription factor that regulates the expression of many genes relevant to carcinogenesis, is now an important target for development of new drugs for the prevention and treatment of cancer. Deficient expression of PPARgamma can be a significant risk factor for carcinogenesis, although in some cases overexpression enhances carcinogenesis. Ligands for PPARgamma suppress breast carcinogenesis in experimental models and induce differentiation of human liposarcoma cells. By analogy to the selective estrogen receptor modulator (SERM) concept, it is suggested that selective PPARgamma modulators (SPARMs), designed to have desired effects on specific genes and target tissues without undesirable effects on others, will be clinically important in the future for chemoprevention and chemotherapy of cancer.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11530334     DOI： 10.1016/s1471-4914(01)02100-1

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN： 1471-4914            Impact factor:   11.951


  39 in total

Review 1.  Novel agents for chemoprevention, screening methods, and sampling issues.

Authors:  Mary Jo Fackler; Ella Evron; Seema A Khan; Saraswati Sukumar
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-01       Impact factor: 2.673

2.  Thiazolidinedione treatment and constitutive-PPARgamma activation induces ectopic adipogenesis and promotes age-related thymic involution.

Authors:  Yun-Hee Youm; Hyunwon Yang; Raj Amin; Steven R Smith; Todd Leff; Vishwa D Dixit
Journal:  Aging Cell       Date:  2010-04-01       Impact factor: 9.304

3.  Profile of David J. Mangelsdorf.

Authors:  Prashant Nair
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-27       Impact factor: 11.205

4.  Suppressive effects of lycopene and β-carotene on the viability of the human esophageal squamous carcinoma cell line EC109.

Authors:  Nguyen Ba Ngoc; Pin Lv; Wen-En Zhao
Journal:  Oncol Lett       Date:  2018-03-05       Impact factor: 2.967

5.  Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines.

Authors:  Karen Bräutigam; Julia Biernath-Wüpping; Dirk O Bauerschlag; Constantin S von Kaisenberg; Walter Jonat; Nicolai Maass; Norbert Arnold; Ivo Meinhold-Heerlein
Journal:  J Cancer Res Clin Oncol       Date:  2010-09-29       Impact factor: 4.553

6.  Inhibitory effect of conjugated alpha-linolenic acid from bifidobacteria of intestinal origin on SW480 cancer cells.

Authors:  Mairéad Coakley; Sebastiano Banni; Mark C Johnson; Susan Mills; Rosaleen Devery; Gerald Fitzgerald; R Paul Ross; Catherine Stanton
Journal:  Lipids       Date:  2008-12-02       Impact factor: 1.880

7.  Peroxisome proliferator-activated receptor (PPAR)gamma is highly expressed in normal human pituitary gland.

Authors:  F Bogazzi; D Russo; M T Locci; B Chifenti; F Ultimieri; F Raggi; P Viacava; D Cecchetti; C Cosci; C Sardella; G Acerbi; M Gasperi; E Martino
Journal:  J Endocrinol Invest       Date:  2005-11       Impact factor: 4.256

8.  Peroxisome proliferator-activated receptor gamma controls Muc1 transcription in trophoblasts.

Authors:  Tali Shalom-Barak; Jill M Nicholas; Yongxu Wang; Xiaowen Zhang; Estelita S Ong; Timothy H Young; Sandra J Gendler; Ronald M Evans; Yaacov Barak
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

9.  Activation of PPARgamma is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cells in vitro.

Authors:  Shizhong Zheng; Anping Chen
Journal:  Biochem J       Date:  2004-11-15       Impact factor: 3.857

10.  Activating peroxisome proliferator-activated receptor gamma mutant promotes tumor growth in vivo by enhancing angiogenesis.

Authors:  Lifeng Tian; Jie Zhou; Mathew C Casimiro; Bing Liang; John O Ojeifo; Min Wang; Terry Hyslop; Chenguang Wang; Richard G Pestell
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.